These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19434314)

  • 1. Immunohistochemical expression and significance of epidermal growth factor receptor (EGFR) in breast cancer.
    Meche A; Cîmpean AM; Raica M
    Rom J Morphol Embryol; 2009; 50(2):217-21. PubMed ID: 19434314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.
    Arnes JB; Bégin LR; Stefansson I; Brunet JS; Nielsen TO; Foulkes WD; Akslen LA
    J Clin Pathol; 2009 Feb; 62(2):139-46. PubMed ID: 18682421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R; Lipponen P; Syrjänen K
    Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria. An immunohistochemical study.
    Wrba F; Reiner A; Ritzinger E; Holzner JH; Reiner G
    Pathol Res Pract; 1988 Feb; 183(1):25-9. PubMed ID: 3362749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.
    DiGiovanna MP; Stern DF; Edgerton SM; Whalen SG; Moore D; Thor AD
    J Clin Oncol; 2005 Feb; 23(6):1152-60. PubMed ID: 15718311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
    Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
    Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
    Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
    Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.
    Sutton LM; Han JS; Molberg KH; Sarode VR; Cao D; Rakheja D; Sailors J; Peng Y
    Am J Clin Pathol; 2010 Nov; 134(5):782-7. PubMed ID: 20959661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
    Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
    Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
    Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
    Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
    Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study.
    Bianchi S; Palli D; Falchetti M; Saieva C; Masala G; Mancini B; Lupi R; Noviello C; Omerovic J; Paglierani M; Vezzosi V; Alimandi M; Mariani-Costantini R; Ottini L
    J Cell Physiol; 2006 Mar; 206(3):702-8. PubMed ID: 16245316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.
    Fink-Retter A; Gschwantler-Kaulich D; Hudelist G; Mueller R; Kubista E; Czerwenka K; Singer CF
    Oncol Rep; 2007 Aug; 18(2):299-304. PubMed ID: 17611648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change?
    Raica M; Jung I; Cîmpean AM; Suciu C; Mureşan AM
    Rom J Morphol Embryol; 2009; 50(1):5-13. PubMed ID: 19221640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 and EGFR expression in cutaneous spindle squamous cell carcinoma.
    Schlauder SM; Calder KB; Moody P; Morgan MB
    Am J Dermatopathol; 2007 Dec; 29(6):559-63. PubMed ID: 18032952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.